209 related articles for article (PubMed ID: 18396671)
1. [Study on the neutralization capacity of different types of human measles virus vaccine and the epidemic strains].
Feng Y; Lu YY; Yan JY; Jiang XH; Shi W; Xu CP; Li Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1123-6. PubMed ID: 18396671
[TBL] [Abstract][Full Text] [Related]
2. [Study on a high coverage of measles vaccine while high incidence of measles disease still appeared in Shaanxi province].
Li P; Si Y; Liu Y; Guan RH
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1096-100. PubMed ID: 18396664
[TBL] [Abstract][Full Text] [Related]
3. [Comparative analysis of measles genome between vaccine strain and wild-type strain in Zhejiang province of China].
Xu CP; Yan JY; Feng Y; Mao HY; Lu YY
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Aug; 43(8):723-6. PubMed ID: 20021855
[TBL] [Abstract][Full Text] [Related]
4. Antibody response after measles immunization.
Ariyasriwatana C; Kalayanarooj S; Pattamadilok S
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S701-6. PubMed ID: 14700170
[TBL] [Abstract][Full Text] [Related]
5. [Measurement of the in vitro immune response of live attenuated measles virus vaccine and antibody levels in 0 to 10-year-old children].
Unalan H; Ustaçelebi S
Mikrobiyol Bul; 1985 Oct; 19(4):218-28. PubMed ID: 3831724
[TBL] [Abstract][Full Text] [Related]
6. Antigenic analysis of wild-type measles viruses currently isolated in Turkey.
Korukluoğlu G; Zarakolu P
Turk J Pediatr; 2006; 48(2):105-8. PubMed ID: 16848107
[TBL] [Abstract][Full Text] [Related]
7. Genetic and antigenic characterization of measles viruses that circulated in Korea during the 2000-2001 epidemic.
Na BK; Shin JM; Lee JY; Shin GC; Kim YY; Lee JS; Lee JK; Cho HW; Lee HJ; Rota PA; Bellini WJ; Kim WJ; Kang C
J Med Virol; 2003 Aug; 70(4):649-54. PubMed ID: 12794731
[TBL] [Abstract][Full Text] [Related]
8. Comparison of neutralizing antibody titers against outbreak-associated measles genotypes (D4, H1 and B3) in Iran.
Fatemi Nasab GS; Salimi V; Abbasi S; Adjami Nezhad Fard F; Mokhtari Azad T
Pathog Dis; 2016 Nov; 74(8):. PubMed ID: 27777263
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibody response variation against dengue 3 strains.
Alvarez M; Pavon-Oro A; Rodriguez-Roche R; Bernardo L; Morier L; Sanchez L; Alvarez AM; Guzmán MG
J Med Virol; 2008 Oct; 80(10):1783-9. PubMed ID: 18712848
[TBL] [Abstract][Full Text] [Related]
10. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
[TBL] [Abstract][Full Text] [Related]
11. Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies.
Muñoz-Alía MA; Casasnovas JM; Celma ML; Carabaña J; Liton PB; Fernandez-Muñoz R
Virus Res; 2017 May; 236():30-43. PubMed ID: 28465158
[TBL] [Abstract][Full Text] [Related]
12. [Analysis on the genotype of measles virus epidemic strains in Dongguan city, Guangdong province in 2000].
Zhu J; Peng Z; Lei M
Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Oct; 22(5):355-8. PubMed ID: 11769691
[TBL] [Abstract][Full Text] [Related]
13. Immune response to measles vaccine in Peruvian children.
Bautista-López NL; Vaisberg A; Kanashiro R; Hernández H; Ward BJ
Bull World Health Organ; 2001; 79(11):1038-46. PubMed ID: 11731811
[TBL] [Abstract][Full Text] [Related]
14. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
[TBL] [Abstract][Full Text] [Related]
15. Measles virus haemagglutination-inhibition antibodies among pregnant and non-pregnant women in the vaccine era in Harare, Zimbabwe.
Obi CL; Tswana SA; Moyo SR; Berejena C
Cent Afr J Med; 1996 May; 42(5):135-8. PubMed ID: 8771931
[TBL] [Abstract][Full Text] [Related]
16. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination.
Cohen BJ; Doblas D; Andrews N
Vaccine; 2008 Nov; 26(50):6392-7. PubMed ID: 18834911
[TBL] [Abstract][Full Text] [Related]
17. Studies on the synthesis of basic proteins and antigenic components in measles virus infected cells.
Polna I; Rzendowska F; Beker J; Hirszfeld G; Sadowski W
Acta Microbiol Pol; 1980; 29(3):273-84. PubMed ID: 19852113
[TBL] [Abstract][Full Text] [Related]
18. Development of a new neutralization test for measles virus.
Fujino M; Yoshida N; Kimura K; Zhou J; Motegi Y; Komase K; Nakayama T
J Virol Methods; 2007 Jun; 142(1-2):15-20. PubMed ID: 17320979
[TBL] [Abstract][Full Text] [Related]
19. Predicting and comparing long-term measles antibody profiles of different immunization policies.
Lee MS; Nokes DJ
Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
[TBL] [Abstract][Full Text] [Related]
20. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005.
Atrasheuskaya AV; Kulak MV; Neverov AA; Rubin S; Ignatyev GM
Vaccine; 2008 Apr; 26(17):2111-8. PubMed ID: 18343536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
